Novo Nordisk/$NVO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Novo Nordisk
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Ticker
$NVO
Sector
Primary listing
NYSE
Employees
67,900
Headquarters
Bagsvaerd, Denmark
Website
Novo Nordisk Metrics
BasicAdvanced
$203bn
10.66
$4.32
0.35
$1.29
3.79%
Price and volume
Market cap
$203bn
Beta
0.35
52-week high
$81.44
52-week low
$35.12
Average daily volume
18m
Dividend rate
$1.29
Financial strength
Current ratio
0.788
Quick ratio
0.541
Long term debt to equity
58.687
Total debt to equity
72.086
Dividend payout ratio (TTM)
42.47%
Interest coverage (TTM)
38.38%
Profitability
EBITDA (TTM)
27,423.723
Gross margin (TTM)
83.20%
Net profit margin (TTM)
37.20%
Operating margin (TTM)
49.25%
Effective tax rate (TTM)
21.66%
Revenue per employee (TTM)
$761,780
Management effectiveness
Return on assets (TTM)
19.25%
Return on equity (TTM)
71.40%
Valuation
Price to earnings (TTM)
10.656
Price to revenue (TTM)
3.96
Price to book
6.35
Price to tangible book (TTM)
17.63
Price to free cash flow (TTM)
42.021
Free cash flow yield (TTM)
2.38%
Free cash flow per share (TTM)
1.096
Dividend yield (TTM)
2.79%
Forward dividend yield
3.79%
Growth
Revenue change (TTM)
8.13%
Earnings per share change (TTM)
16.75%
3-year revenue growth (CAGR)
20.30%
10-year revenue growth (CAGR)
11.54%
3-year earnings per share growth (CAGR)
26.65%
10-year earnings per share growth (CAGR)
15.10%
3-year dividend per share growth (CAGR)
23.58%
10-year dividend per share growth (CAGR)
13.84%
What the Analysts think about Novo Nordisk
Analyst ratings (Buy, Hold, Sell) for Novo Nordisk stock.
Novo Nordisk Financial Performance
Revenues and expenses
Novo Nordisk Earnings Performance
Company profitability
Novo Nordisk News
AllArticlesVideos
Oral Ozempic and Wegovy pills now available for same-day delivery on Amazon
New York Post·5 hours ago
Wegovy pill on track for blockbuster status as Novo Nordisk navigates crowded GLP-1 market
Proactive Investors·23 hours ago
Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk
CNBC·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novo Nordisk stock?
Novo Nordisk (NVO) has a market cap of $203B as of May 09, 2026.
What is the P/E ratio for Novo Nordisk stock?
The price to earnings (P/E) ratio for Novo Nordisk (NVO) stock is 10.66 as of May 09, 2026.
Does Novo Nordisk stock pay dividends?
Yes, the Novo Nordisk (NVO) stock pays dividends to shareholders. As of May 09, 2026, the dividend rate is $1.28523 and the yield is 3.79%. Novo Nordisk has a payout ratio of 42.47% on a trailing twelve-month basis.
When is the next Novo Nordisk dividend payment date?
The next Novo Nordisk (NVO) dividend payment date is unconfirmed.
What is the beta indicator for Novo Nordisk?
Novo Nordisk (NVO) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.